27 completed, 2 active not recruiting, 2 recruiting, 2 unknown. 19 Phase 2, 8 Phase 1, 5 Phase 3, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 14, Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 8 | Completed 7, Recruiting 1 |
| Phase 3 | 5 | Completed 3, Active not recruiting 2 |
| Phase 4 | 3 | Completed 2, Unknown 1 |
Follow Philadelphia Chromosome: new trials by email Literature Review of Philadelphia Chromosome trials Research Report on Philadelphia Chromosome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL Prednisone, Olverembatinib, Blinatumomab, Chidamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 67 | 2024-02-01 | 2024-01-24 |
| Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy - Acute Lymphoblastic Leukemia | Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2024-01-01 | 2024-02-22 | |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-16 |
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) Asciminib, Nilotinib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 568 | 2022-11-21 | 2026-08-26 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland Bosutinib - Myeloid Leukemia | Completed | Pfizer | 17 | 2019-05-01 | 2026-06-29 | |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL Inotuzumab ozogamicin (INO) - Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) | Phase 2 | Completed | Versailles Hospital | 131 | 2017-12-28 | 2026-06-22 |
| Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Non-Interventional - Chronic Myeloid Leukemia, Philadelphia Chromosome | Completed | Bristol-Myers Squibb | 463 | 2017-11-30 | 2022-06-27 | |
| Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Dasatinib, prednisone, cyclophosphamide - Acute,Leukemia, Lymphoid | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2015-08-01 | 2026-02-11 |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Bosutinib, Imatinib - Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | Phase 3 | Completed | Pfizer | 536 | 2014-07-15 | 2021-05-18 |
| TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia TKIs - Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 80 | 2013-06-01 | 2017-11-08 |
| Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Idarubicin(IDA) - Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent | Phase 4 | Unknown | Chinese Academy of Medical Sciences | 20 | 2012-10-01 | 2013-11-21 |
| Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2012-08-08 | 2020-03-05 |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Melphalan, Fludarabine, Mycophenolate mofetil - Blood And Marrow Transplantation, Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2012-07-13 | 2017-04-28 |
| Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) Dasatinib - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 2 | Completed | Goethe University | 19 | 2011-11-01 | 2022-01-26 |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) PEG-IFNá-2a - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2011-10-01 | 2015-05-04 |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Imatinib, Radotinib - Leukemia, Leukemia, Myeloid | Phase 3 | Completed | Il-Yang Pharm. Co., Ltd. | 242 | 2011-08-01 | 2016-02-24 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 421 | 2011-04-01 | 2016-03-03 |
Showing 20 of 35. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (22) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Leukemia (11) · Leukemia, Myeloid (4) · Leukemia, Myeloid, Acute (4) · Hematologic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Neoplasm, Residual (3) · Blast Crisis (2) · Bone Marrow Diseases (2) · Burkitt Lymphoma (2) · Leukemia, B-Cell (2) · Lymphoma, B-Cell (2)
Chromosome Aberrations (35) · Hemic and Lymphatic Diseases (35) · Neoplasms (35) · Pathological Conditions, Signs and Symptoms (35) · Neoplasms by Histologic Type (34) · Pathologic Processes (34) · Translocation, Genetic (34) · Hematologic Diseases (32) · Leukemia (24) · Chronic Disease (22) · Disease Attributes (22) · Myeloproliferative Disorders (21) · Bone Marrow Diseases (20) · Leukemia, Myeloid (19) · Immune System Diseases (17)
Imatinib Mesylate (14) · Dasatinib (5) · Cyclophosphamide (4) · bosutinib (4) · nilotinib (4) · Cytarabine (3) · Dexamethasone (3) · Methotrexate (3) · Vincristine (3) · fludarabine (3) · 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (2) · Acetaminophen (2) · Azacitidine (2) · Daunorubicin (2) · Prednisone (2)
Novartis Pharmaceuticals (9) · M.D. Anderson Cancer Center (3) · Pfizer (3) · Il-Yang Pharm. Co., Ltd. (2) · Nanfang Hospital, Southern Medical University (2) · National Cancer Institute (NCI) (2) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Chinese Academy of Medical Sciences (1) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (1) · Goethe University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Japan Adult Leukemia Study Group (1) · Norwegian University of Science and Technology (1) · Novartis (1)
United States (13) · France (10) · Germany (10) · China (8) · Italy (8) · United Kingdom (8) · South Korea (7) · Canada (5) · Finland (5) · Hungary (5) · India (5) · Netherlands (5) · Norway (5) · Sweden (5) · Australia (4)
Alfonso Quintas-Cardama, MD (1) · Andrea Biondi, MD (1) · Andreas Hochhaus, Professor, MD (1) · Bengt Simonsson, MD, PhD (1) · Congcong Wang (1) · Elizabeth Shpall, MD (1) · Fumihiko Hayakawa, MD (1) · Henrik Hjorth-Hansen, MD, PhD (1) · Hongsheng Zhou, M.D., Ph.D (1) · IL-yang Pharm (1) · Ingunn Dybedal, MD, PhD (1)
PMID 35235189, PMID 15315963, PMID 16344315, PMID 18223280, PMID 21865346, PMID 22036634, PMID 22371878, PMID 22898679, PMID 23116602, PMID 23328954, PMID 24345751, PMID 24705186, PMID 24711212, PMID 24919837, PMID 25082346, PMID 25761894, PMID 25778529, PMID 27006491, PMID 27045164, PMID 27531525, PMID 28522574, PMID 28699641, PMID 28939746, PMID 29072772, PMID 29091516, PMID 29773593, PMID 30501871, PMID 33204013, PMID 33242441, PMID 33851349, PMID 33858040, PMID 34120773, PMID 34673442, PMID 34687939, PMID 34889384, PMID 35605184, PMID 35643868, PMID 36524980, PMID 37486616, PMID 37553873, PMID 38376944, PMID 38820078, PMID 39418626, PMID 41397287, PMID 42248607, PMID 42339511
2005 (4), 2008 (1), 2009 (1), 2016 (1), 2023 (1), P01CA148600 (1)